Zepbound, Eli Lilly and Medicare

Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month.Weight loss drugs like Zepbound and Novo Nordisk's Ozempic aren't covered under Medicare,
Medicare To Cover Eli Lilly's Weight Loss Drug Zepbound For Obstructive Sleep Apnea Treatment
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, reducing apnea events by 62.8%.
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday statement from the Centers for Medicare & Medicaid Services comes after Zepbound in December became the first drug approved in the U.
Lilly Wins Medicare Coverage for Zepbound in Sleep Apnea
According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to secure CMS coverage for obesity drugs.
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea
The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug
Eli Lilly Says FDA Approves Zepbound for Obstructive Sleep Apnea in Adults With Obesity
Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.
Medicare may cover Eli Lilly’s Zepbound for sleep apnea: Department of Health and Human Services agency
Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, sleep apnea and more. To be covered, these drugs would need to have late-stage trial results and then seek FDA approval for these uses.
FDA approves first medication for obstructive sleep apnea — which also promotes weight loss
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The First Sleep Apnea Drug Is Here
“This is the first pharmacologic therapy that can treat obstructive sleep apnea in this way,” says Dan Skovronsky, chief ...